Generic semaglutide in Canada: what Felix's waitlist (and the 65% number) actually mean

When Felix Health launched a generic semaglutide waitlist this month, the announcement set off a wave of social media posts — including a circulating Reddit thread — framing it as a "65% price cut." That number is real, but the timing and conditions behind it are getting lost in translation. Here's the honest breakdown of what just happened, what it means for your monthly cost, and what to actually do next.

What actually happened

Health Canada approved two generic semaglutide products in the past two weeks:

• Dr. Reddy's Laboratories — approved April 28, 2026
• Apotex (Apo-Semaglutide Injection) — approved May 1, 2026

Both approvals are for the Type 2 diabetes indication only — the equivalent of generic Ozempic. Seven additional generic submissions remain under Health Canada review. In response, Felix Health (and almost certainly other telehealth providers in the coming weeks) launched a waitlist page inviting patients to register for updates when generic supply reaches their dispensaries.

The "coming weeks" timeline Felix mentions is plausible — manufacturers have indicated they expect product on Canadian pharmacy shelves shortly after approval — but approval is not the same as availability, and availability is not the same as the deepest price tier.

The 65% number, in context

Canada has a structured generic drug pricing framework — the pan-Canadian Tiered Pricing Framework, administered through the pan-Canadian Pharmaceutical Alliance — that ratchets prices down as more generic manufacturers enter a market. It is a staircase, not a single step, and there's an automatic step-down built in even at the single-generic stage.

Using the current manufacturer list price for Ozempic of approximately $228 for a four-week supply (the official "brand reference price," before pharmacy and distributor markups), the framework caps generic prices as follows:

Stage	Generic price cap	Reduction from brand list
1 generic, first 3 months	75% of brand (~$171)	~25% off
1 generic, after 3 months	55% of brand (~$125)	~45% off
2 generics	50% of brand (~$114)	~50% off
3 or more generics (injectables)	35% of brand (~$80)	~65% off

These are list-price caps for public drug plan formularies. Retail prices you'll see at a pharmacy include dispensing fees and markups, so absolute dollar figures will be higher than the table — but the percentage reductions track proportionally.

In plain terms: with two manufacturers approved in May 2026 and pharmacy launches just beginning, the realistic near-term consumer price reduction lands in the 25–50% range, depending on which manufacturers are actively dispensing in your province. The 65% figure represents the floor reached only after three or more manufacturers are simultaneously on market — likely a multi-quarter process as the remaining seven applications work through review and production scale-up.

This isn't a criticism of any provider's communication — it's just how the framework works. Anyone framing 65% as today's price is compressing the timeline.

Wegovy is not part of this — yet

This is the most important piece of fine print, and the part most patients miss.

The generic semaglutide approvals so far reference Ozempic as the brand-name comparator. Both Dr. Reddy's and Apotex were authorized for the 2 mg/pen and 4 mg/pen formats and the Type 2 diabetes indication — the standard Ozempic configuration. Wegovy, which uses the same semaglutide molecule at higher weekly doses (up to 2.4 mg) and is approved by Health Canada specifically for chronic weight management, has no generic equivalent yet.

The reason isn't patent protection. Novo Nordisk's Canadian patent on semaglutide lapsed in 2020, and data exclusivity for both Ozempic and Wegovy expired on January 4, 2026. The regulatory path for a generic Wegovy is open. The actual reason no generic exists yet is that no manufacturer has filed an Abbreviated New Drug Submission (ANDS) referencing Wegovy specifically — demonstrating bioequivalence at the higher Wegovy doses and pursuing the weight-management indication is a separate regulatory exercise from the diabetes-indication ANDS filings that have just cleared. At least one manufacturer (PharmaTher) has announced it is targeting the full 0.25–2.4 mg dose range, suggesting Wegovy-equivalent generics are likely later in 2026 or in 2027.

What this means in practice:

• If your prescription is for Ozempic (the diabetes-indication brand), you'll be eligible to switch to generic semaglutide once your dispensing pharmacy stocks it. This applies whether you take Ozempic for blood sugar management or off-label for weight loss.
• If your prescription is specifically for Wegovy, generic substitution is not currently an option in Canada — there is no approved generic to substitute. That may change as additional ANDS filings clear.
• Patients using off-label Ozempic for weight management — a significant share of Canadian GLP-1 users — will see the price benefit on the same timeline as diabetes patients.

If you're not sure which brand your prescription specifies, your pharmacist or prescribing provider can confirm.

When will pharmacies actually have it?

Approval is the regulatory milestone. Availability is a separate process involving manufacturer production scale-up, wholesaler distribution, and provincial supply chain logistics. Both Dr. Reddy's and Apotex have signalled that generic semaglutide should reach Canadian pharmacies within weeks of approval, but realistic expectations for the first few months include:

• Limited initial supply, with some doses (especially higher strengths) reaching pharmacies before others
• Uneven geographic rollout — large urban pharmacy chains will likely list first
• Provincial coverage decisions still pending for most public drug plans, with private insurers expected to encourage or require generic substitution where therapeutically equivalent

What to do right now

The most useful action depends on where you are in your treatment:

• If you're an existing Ozempic patient, talk to your prescriber about a switch to generic semaglutide once your pharmacy confirms stock. The active ingredient, dose, and delivery are identical; the savings begin as soon as the generic is dispensed.
• If you're researching starting a GLP-1, the price comparison logic hasn't fundamentally changed yet — branded Ozempic and Wegovy are still the products most pharmacies stock today. Our pharmacy price comparison reflects current cash prices and will update as generic pricing becomes available pharmacy-by-pharmacy.
• Evaluate provider-specific announcements in context. Waitlists and "exclusive early access" framing are marketing mechanisms. Generic semaglutide, once dispensed, will be available at every licensed Canadian pharmacy that chooses to stock it — not gated to any single telehealth provider.

We're tracking each generic semaglutide approval, expected market date, and pharmacy-level availability publicly and provider-neutrally. Check the Generic Semaglutide Tracker for live status and to get notified when generic prices first appear in your province.

---

GLP1Prices.ca is independent and not affiliated with any pharmacy, manufacturer, or telehealth provider. Pricing information is collected through direct pharmacy surveys and public sources. This article is for educational purposes and does not substitute for medical advice from a licensed healthcare provider.